Special Issues

2020 Year in Review - Biosimilars

This review will provide the oncology care team with information on the latest research developments and insights into best practices in the use of biosimilars to enhance their management of patients with cancer, leading to an improvement in clinical outcomes.

2020 Year in Review - Ovarian Cancer

Shared Supplements

This review will provide the oncology care team with information on the latest research developments and insights into best practices in treating ovarian cancer to enhance their management of patients with this disease, leading to an improvement in clinical outcomes.

TON - Evolving Guidelines

TON - Supplements

Epithelial ovarian cancer is the fifth leading cause of cancer mortality in women and is the leading cause of death due to gynecologic cancer in the United States.

Clinical Trials to Clinical Practice

TON - Supplements

Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events - TON

TON - Supplements

Faculty Perspectives: Considerations in Metastatic Colorectal Cancer: Practical Applications and Patient Management for Oncology Nurses and Pharmacists

Andrea L. McNatty, PharmD, RPh, Kelley A. Rone, APRN, DNP, Tanios S. Bekaii-Saab, MD, FACP

TON - Supplements

There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.

Best Practices in Patient Navigation – Navigating Hematologic Malignancies

TON - Supplements

Faculty Perspectives: Next-Generation Sequencing Testing in Oncology || Part 4 of a 4-Part Series

TON - Supplements

Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. These advancements were driven by molecular profiling that enabled the identification of those patient populations most likely to benefit from targeted therapy and/or immunotherapy—that is, precision medicine.

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

TON - Supplements

There is renewed interest in MSI analysis because the MSI-H/dMMR phenotype has emerged as an actionable predictive biomarker for immune checkpoint blockade therapy in different cancer types. This review presents available evidence supporting the clinical relevance and predictive value of MSI/dMMR in cancers, including those treated with immune checkpoint inhibitors (ICIs), and outlines the diagnostic approaches developed to assess MSI/dMMR in clinical practice.

Faculty Perspectives: Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology | Part 2 of a 4-Part Series

TON - Supplements

PD-L1 expression is a rational biomarker to predict response to PD-1/PD-L1 ICI therapy, and has been studied extensively in clinical trials. A recurring theme emerging from available clinical data is that high levels of tumor cell membrane PD-L1 expression correlate with better outcomes with PD-1/PD-L1 blockade.

Page 1 of 5
Results 1 - 10 of 50